Oragenics

Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced it is preparing for a Phase II clinical trial using its novel drug - device combination for the treatment of mild Traumatic Brain Injury, aka concussion. Oragenics' lead drug candidate, ONP-002, is a new chemical entity (NCE) designed to target the brain through self-propelled powdered.

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering program. The Company has initiated the 5-day termination process of the ATM offering, with the termination to take effect on January 30, 2024. The Company will make no sales under the ATM offering during this period. This press release does not constitute an offer to sell or the solicitation of an of.

Oragenics Announces Termination of At-The-Market Offering Program

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.'s (OTCQB: ODYY) (“Odyssey”) proprietary neurological drug therapies and technologies. The acquired assets include ONP-002 and a unique nasal delivery device, Odyssey's lead concussion asset, believed to be a first-in-class intranasal drug under development for the treatment of moderate-to-seve.

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN): Fellow Shareholders, As our annual meeting date approaches and in response to valuable feedback from our shareholders, I believe it important to highlight and summarize some of the information in our proxy statement regarding the proposed increase in our authorized shares as well as our cost-saving efforts. Odyssey Asset Purchase On October 5, 2023, we proudly announced that we had entered into an agreement to acquire Odyssey.

Oragenics Issues Update to Shareholders

LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is providing an update on its Asset Purchase Agreement with Oragenics, Inc. (NYSE: OGEN). When the Asset Purchase Agreement is consummated, Odyssey will receive eight (8) million shares of Oragenics Series F Convertible Preferred Stock at the close of the transaction.

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. “We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board,” said Charlie Pope, Chairman of Oragenics. “Bruce's deep experience in high-technology global businesses will be invaluable to Oragenics as we grow our portfolio. John's proven leadership in the life.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

TAMPA, Fla. & LAS VEGAS--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey's assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as.

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics' biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts. Under this agreement, Oragenics has received.

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the “Private Placement Offering”), an aggregate of (i) 404,728 shares of the Company's common stock, $0.001 par value (the “Common Stock”), and (ii) 404,728 shares of.

Oragenics, Inc. Announces Private Placement

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant from CQDM, a Canadian bioresearch consortium, for the collaborative development of a variant-agnostic COVID-19 protein subunit vaccine candidate. The project, which aims to build upon Oragenics' current lead intranasal vaccine candidate NT-CoV2-1, is a collaboration with the National Research Council.

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C. Ms.

Oragenics to Participate in the World Vaccine Congress Washington

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics' lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies.

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, Oragenics' lead intranasal COVID-19 vaccine candidate.

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

TAMPA, Fla.--( BUSINESS WIRE )--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American's continued listing standards.

Oragenics, Inc. Regains Compliance with NYSE American

Cemtrex

Sientra

The Beauty Health Company

Sitio Royalties Corp

Warby Parker

Clear Secure

As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white sharks.

7 Short-Squeeze Stocks to Buy Before They Soar

Metacrine

Agrify

Express

Pagaya Technologies Ltd

Seanergy Maritime Hlds

Vislink Technologies Inc

Penny stocks to buy under $1: A Beginner's Guide The post Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch

TAMPA, Fla.--( BUSINESS WIRE )--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the “Board”) on December 22, 2022 approved a 1-for-60 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company's authorized shares of common stock (the “Reverse Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares. As a result of the Reverse Stock Split, the Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on January 23, 2023.

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

TAMPA, Fla.--( BUSINESS WIRE )--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate. Oragenics believes the findings of the final toxicology report, including a full histopathology evaluation, confirm a safety and immunogenicity profile that further support its plan to submit regulatory filings required to progress to a Phase 1 clinical study.

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

TAMPA, Fla.--( BUSINESS WIRE )--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice (the “Notice”) on December 19, 2022 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").

Oragenics, Inc. Receives NYSE American Notice

TAMPA, Fla.--( BUSINESS WIRE )--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011. Dr. Telling will remain on the Board as an independent director and as a member of both the audit and nominating and corporate governance committees.

Oragenics, Inc. Announces New Chair

Oragenics to Participate in the 2022 BioFlorida Annual Conference

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy. To My Fellow Shareholders, As COVID-19 continues to impact the world's population – albeit with far less dire consequences due to the availability of vaccines, therapeutics and better in-hospital care of

Oragenics Issues Letter to Shareholders

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

News for Oragenics Stock (OGEN)